{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"19.5","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The criteria for sCR, CR, VGPR, and PR based on IMWG are shown below.\n\nsCR: Fulfills CR criteria as well as all of the following conditions\n\n* Normal free light chain (FLC) ratio(κ/λ)\n* Disappearance of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\n\nCR: Fulfills all of the following criteria\n\n* Negative immunofixation of serum and urine M-protein\n* \\<5% plasma cells in bone marrow\n* Disappearance of any soft tissue plasmacytoma\n\nVGPR: Fulfills at least one of the following criteria\n\n* Serum and urine M-protein detectable by immunofixation but not electrophoresis\n* ≥90% reduction in serum M-protein and 24-hour M-protein excretion amount in urine \\<0.1 g/24 hour\n\nPR: Fulfills the following criteria\n\n* ≥50% reduction in serum M-protein, and ≥90% reduction in urine M-protein, urine M-protein excretion amount is reduced to \\< 0.2 g/24hours","dispersionType":"95% Confidence Interval","groups":[{"description":"SyB L-0501: The administration of SyB L-0501 at 90 mg/m\\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.","id":"OG000","title":"SyB L-0501"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to around 44 weeks","title":"Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria","type":"PRIMARY","unitOfMeasure":"percentage of paticipants"}